Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesInjuries, Poisonings and Toxic Effects of DrugsDRG 913-traumatic-injury-with-mcc
    Ask Trek AI about this page

    Traumatic Injury with MCC: Inpatient Reimbursement Overview

    DRG 913 encompasses severe traumatic injury admissions with a Major Complication or Comorbidity that drive higher clinical complexity and resource needs. Correct assignment affects inpatient reimbursement because Medicare Severity Diagnosis-Related Group payment is adjusted upward to account for increased expected costs associated with major complications or comorbidities.

    Customize your policy alerts

    Sign up for drg 913 policy alerts

    Get alerted when payer policies referencing 913 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 913 Overview

    DRG 913 covers inpatient stays for patients admitted with severe traumatic injuries accompanied by a Major Complication or Comorbidity, reflecting high clinical complexity and resource use. This Diagnosis-Related Group groups cases where trauma care requires intensive interventions, extended monitoring, or multiple specialties. It matters for Medicare payment because classification into this DRG typically yields higher reimbursement to reflect greater expected costs and longer lengths of stay. Accurate coding and documentation of the Major Complication or Comorbidity drive appropriate assignment to this DRG.

    Table of contents

    Progress1 / 5

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    National Payment Rates

    Across payers, negotiated rates for DRG 913 range from about $8.4K (BCBS minimum) up to $53K (Anthem maximum), with mean payer-specific averages spanning roughly $13K to $27K. The widest spread between payer minima and maxima appears in the Anthem and Cigna data, showing substantial variability across commercial payers. See the table and chart below for payer-level detail and distributional context.

    The CMS 2023 data represent national Medicare fee-for-service inpatient payments as reported in the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($15.5k), average submitted covered charges ($75.2k), average Medicare payment amount ($12.9k), and total discharges (809).

    Average Total PaymentAverage Submitted ChargesAverage Medicare PaymentTotal Discharges
    $15K$75K$13K810

    Patient Population

    This DRG population is mixed but leans toward Medicare-age patients given the Medicare dataset and typical inpatient utilization patterns; many discharges in the CMS table reflect Medicare fee-for-service beneficiaries. Commercial payers (Cigna, Aetna, Anthem, BCBS) contribute a meaningful share, indicating a non-trivial working-age component as well. Overall the population spans both working-age and Medicare-age groups, with a heavier concentration among Medicare-age beneficiaries.

    State Payment Rates

    State: Alaska1 / 49

    Alaska Benchmarks

    DRG 913 in Alaska shows a payer rate range from about $7.5K up to $70K across observed payers, with most payers clustering near $24K–$25K while Cigna stands out at a substantially higher mean and median. The divergence is most pronounced at the upper end where Cigna’s p75 and max push the state distribution above typical national medians. See the table and chart below for the payer-level detail and distribution.

    Key Insights for Alaska

    • Highest payer: Cigna (median $39K; mean $41K), notably above other local payers.
    • Lowest payer: Blue Cross Blue Shield (BCBS) and Anthem (median $25K; mean $24K) at the low end of the state range.
    • Meaningful deviation: Cigna’s mean and upper quartile (mean $41K; p75 $66K) sit well above national medians, creating a wider state spread compared with national benchmarks.

    Clinical Trials

    • Acute hemostasis and resuscitation trials: randomized or pragmatic studies testing different strategies for early hemorrhage control, blood product ratios, and damage-control resuscitation protocols in severely injured adults with life‑threatening blunt or penetrating trauma and multiple comorbidities. These trials enroll patients in the emergency department or operating room, often within hours of injury, to evaluate immediate mortality, transfusion requirements, and complications such as coagulopathy and organ failure. Findings are directly relevant to hospitals and payers because they inform resource use in the highest‑acuity phase of care, influence length of stay in intensive care units, and affect short‑term mortality and complication costs for DRG 913 cases.
    • Comparative effectiveness studies of surgical vs nonoperative management and timing of definitive fracture or organ repair: cohort studies and randomized trials comparing early definitive fixation or operative repair versus staged or nonoperative approaches in traumatically injured patients who also have major comorbid conditions (for example, older adults with osteoporosis, cardiovascular disease, or chronic anticoagulation). These studies focus on functional outcomes, complication rates (infection, thromboembolism), readmission, and cumulative inpatient days across the index hospitalization and early post‑discharge period. Results help clinicians and payers understand tradeoffs between upfront operative resource use and downstream costs from complications or prolonged rehabilitation, guiding care pathways and reimbursement risk adjustment for complex trauma patients.
    • Post‑discharge outcomes and rehabilitation trials: longitudinal studies and randomized trials of inpatient-to-community transitions, early intensive rehabilitation, and secondary prevention interventions for survivors of traumatic injury with major complications (for example, patients discharged with disability after traumatic brain injury, spinal cord injury, or multisystem trauma). These trials measure long‑term functional recovery, quality of life, return to work, and utilization of home health and readmissions over months to years. For providers and payers, this research is crucial because improvements in post‑acute care and coordinated discharge planning can reduce costly readmissions, long‑term institutionalization, and overall total cost of care for patients classified under DRG 913.

    Related Codes

    901-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITH-MCC

    Wound Debridements for Injuries with MCC: Inpatient Reimbursement Overview

    902-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITH-CC

    Wound Debridements for Injuries with CC: Inpatient Reimbursement Overview

    903-WOUND-DEBRIDEMENTS-FOR-INJURIES-WITHOUT-CC-MCC

    Wound Debridements for Injuries without CC/MCC: Inpatient Reimbursement Overview

    904-SKIN-GRAFTS-FOR-INJURIES-WITH-CC-MCC

    Skin Grafts for Injuries with CC/MCC: Inpatient Reimbursement Overview

    905-SKIN-GRAFTS-FOR-INJURIES-WITHOUT-CC-MCC

    Skin Grafts for Injuries without CC/MCC: Inpatient Reimbursement Overview

    906-HAND-PROCEDURES-FOR-INJURIES

    Hand Procedures for Injuries: Inpatient Reimbursement Overview

    907-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-MCC

    Other O.R. Procedures for Injuries with MCC: Inpatient Reimbursement Overview

    908-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITH-CC

    Other O.R. Procedures for Injuries with CC: Inpatient Reimbursement Overview

    909-OTHER-O-R-PROCEDURES-FOR-INJURIES-WITHOUT-CC-MCC

    Other O.R. Procedures for Injuries without CC/MCC: Inpatient Reimbursement Overview

    914-TRAUMATIC-INJURY-WITHOUT-MCC

    Traumatic Injury without MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 19

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    Mean Rates by Payer — National — DRG 913
    Mean Rates by Payer — Alaska — DRG 913